Antibe Therapeutics, Inc.

Antibe Therapeutics, Inc.

Antibe Therapeutics, Inc.

Overview
Date Founded

2009

Headquarters

15 Prince Arthur Avenue, Toronto, ON, M5R 1B2, CAN

Type of Company

Public

Employees (Worldwide)

38

Industries

Pharmaceuticals
Medical Support Services
Biotechnology

Company Description

Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. It operates through the Antibe Therapeutics, and Citagenix segments. The Antibe Therapeutics segment focuses on the development of pharmaceutical products. The Citagenix segment involves in the development and sale of regenerative medicines serving the dental and orthopedic market places. The company was founded by Andre Buret, John Wallace and Giuseppe Cirino on May 5, 2009 and is headquartered in Toronto, Canada.

Contact Data
Trying to get in touch with decision makers at Antibe Therapeutics, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Founder

Chief Financial Officer

Chief Commercial Officer

Chief Development Officer

Chief Medical Officer

Head-Regional Business Development

Executive Vice President-Corporate Development

Vice President Investor Relations

Vice President Drug Development

Vice President Communications

Board of Directors

Former President of International Markets at MasterCard, Inc.

Former Chief Financial Officer at Polaris Group

Vice President, Business Development at Knight Therapeutics, Inc.

President & Chief Executive Officer at Antibe Holdings, Inc.

Founder at Antibe Therapeutics, Inc.

Professor at St. Bartholomew's Hospital

Chief Executive Officer at MaRS Discovery District

Vice President of Investor Relations & Strategy at Calithera Biosciences, Inc.

Paths to Antibe Therapeutics, Inc.
Potential Connections via
Relationship Science
You
Antibe Therapeutics, Inc.
Recent Transactions
Details Hidden

Antibe Therapeutics, Inc. issued CAD Units Consisting of Common Shares and Warrants - Bought Deal

Details Hidden

Antibe Therapeutics, Inc. raised money in a private placement transaction

Details Hidden

Antibe Therapeutics, Inc. issued CAD Units Consisting of Common Stock and Warrants

Transaction Advisors
Underwriter

Advised onAntibe Therapeutics, Inc. issued CAD Units Consisting of Common Shares and Warrants - Bought Deal

Escrow Agent

Advised onAntibe Therapeutics, Inc. issued CAD Units Consisting of Common Shares and Warrants - Bought Deal

Underwriter

Advised onAntibe Therapeutics, Inc. issued CAD Units Consisting of Common Stock and Warrants

Legal Advisor

Advised onAntibe Therapeutics, Inc. issued CAD Units Consisting of Common Shares and Warrants - Bought Deal

Legal Advisor

Advised onAntibe Therapeutics, Inc. issued CAD Units Consisting of Common Shares and Warrants - Bought Deal

Legal Advisor

Advised onAntibe Therapeutics, Inc. issued CAD Units Consisting of Common Shares and Warrants - Bought Deal

Advisors & Consultants
Advisor

Vice President Investor Relations at Antibe Therapeutics, Inc.

Clients

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its products include ILUVIEN, Nerlynx, Probuphine, Movantik, and Neuragen. The company was founded by Jonathan R. Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

Key Stats and Financials As of 2020
Market Capitalization
$93.4M
Total Enterprise Value
$114M
Earnings Per Share
$-0.5
EBITDAMargin
-169.13%
Enterprise Value / Sales
16.27x
TEVNet Income
-8.4x
Debt TEV
0.01x
Revenue
$7.02M
Three Year Compounded Annual Growth Rate Of Revenue
3.32%
Net Profit
$-13.6M
EBITDA
$-11.9M
Total Debt
$1.68M
Total Equity
$2.66M
Investors
Details Hidden

AVAC invests in companies located in Alberta. The firm targets companies operating in the fields of information & communications technology, energy technology, life sciences, agriculture and biotech. It provides financing for early stage capital requirements and makes investments up to $0.25 million per company and also co-invest with other angel investors.

Details Hidden

Founder at Antibe Therapeutics, Inc.

Suppliers
HansBiomed Co., Ltd. Hospitals & Patient Services | Seoul, South Korea

HansBiomed Co., Ltd. engages in the manufacture and sale of graft material and silicon products. Its products include skin and bone graft material, silicon material, and other medical appliances. The company was founded on September 15,1999 and is headquartered in Seoul, South Korea.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Antibe Therapeutics, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Antibe Therapeutics, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Antibe Therapeutics, Inc..